BR0308806A - Uso de oxazolidinonas para tratar infecções do tipo pé diabético - Google Patents

Uso de oxazolidinonas para tratar infecções do tipo pé diabético

Info

Publication number
BR0308806A
BR0308806A BR0308806-5A BR0308806A BR0308806A BR 0308806 A BR0308806 A BR 0308806A BR 0308806 A BR0308806 A BR 0308806A BR 0308806 A BR0308806 A BR 0308806A
Authority
BR
Brazil
Prior art keywords
diabetic foot
oxazolidinones
treat diabetic
foot infections
infections
Prior art date
Application number
BR0308806-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Carl Norden
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of BR0308806A publication Critical patent/BR0308806A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR0308806-5A 2002-03-29 2003-03-21 Uso de oxazolidinonas para tratar infecções do tipo pé diabético BR0308806A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36910402P 2002-03-29 2002-03-29
PCT/US2003/008882 WO2003084534A1 (en) 2002-03-29 2003-03-21 Parenteral, intravenous, and oral administration of oxazolidinones for treating diabetic foot infections

Publications (1)

Publication Number Publication Date
BR0308806A true BR0308806A (pt) 2005-01-04

Family

ID=28791924

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308806-5A BR0308806A (pt) 2002-03-29 2003-03-21 Uso de oxazolidinonas para tratar infecções do tipo pé diabético

Country Status (16)

Country Link
US (1) US20030216330A1 (enExample)
EP (1) EP1490059A1 (enExample)
JP (1) JP2005527575A (enExample)
KR (1) KR20040095328A (enExample)
CN (1) CN1642543A (enExample)
AU (1) AU2003223334A1 (enExample)
BR (1) BR0308806A (enExample)
CA (1) CA2476545A1 (enExample)
IL (1) IL164195A0 (enExample)
MX (1) MXPA04009356A (enExample)
NO (1) NO20044672L (enExample)
NZ (1) NZ535648A (enExample)
PL (1) PL372661A1 (enExample)
RU (1) RU2354372C2 (enExample)
WO (1) WO2003084534A1 (enExample)
ZA (1) ZA200407734B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200404069A (en) * 2002-06-28 2004-03-16 Upjohn Co Difluorothioacetamides of oxazolidinones with a glycoloylpiperazine substituent
JP4579502B2 (ja) * 2003-05-02 2010-11-10 キヤノン株式会社 構造体及びその製造方法、該構造体を含むトナー並びにそれを用いた画像形成方法及び装置
US8324398B2 (en) 2003-06-03 2012-12-04 Rib-X Pharmaceuticals, Inc. Process for the synthesis of biaryl oxazolidinones
AU2004267007C1 (en) 2003-06-03 2010-04-29 Melinta Subsidiary Corp. Biaryl heterocyclic compounds and methods of making and using the same
US7129259B2 (en) 2003-12-17 2006-10-31 Rib-X Pharmaceuticals, Inc. Halogenated biaryl heterocyclic compounds and methods of making and using the same
WO2006008640A1 (en) * 2004-07-15 2006-01-26 Pharmacia & Upjohn Company Llc Non-aqueous suspension containing a drug having an unpleasant taste
TW200612923A (en) * 2004-07-29 2006-05-01 Ferrer Int Oxazolidinone compounds and compositions and methods related thereto
DE602006019870D1 (de) 2005-06-08 2011-03-10 Rib X Pharmaceuticals Inc Verfahren zur synthese von triazolen
EP1745784A1 (en) * 2005-06-27 2007-01-24 Ferrer Internacional, S.A. Oxazolidinone derivatives and use thereof as antibiotics
JP2008544979A (ja) 2005-06-29 2008-12-11 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 抗菌剤としてのホモモルホリンオキサゾリジノン
WO2009032470A2 (en) * 2007-08-22 2009-03-12 Trustees Of Dartmouth College Compositions and methods for diagnosing and treating community-acquired methicillin-resistant staphylococcus aureus
TW201036609A (en) * 2009-03-16 2010-10-16 Astrazeneca Ab Compound for the treatment of tuberculosis
US9795601B2 (en) * 2010-12-15 2017-10-24 Biovista, Inc. Compositions and methods for cancer treatment

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4705799A (en) * 1983-06-07 1987-11-10 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl benzenes useful as antibacterial agents
US5043443A (en) * 1988-07-29 1991-08-27 Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives
US5254577A (en) * 1988-07-29 1993-10-19 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US5225565A (en) * 1988-09-15 1993-07-06 The Upjohn Company Antibacterial 3-(fused-ring substituted)phenyl-5β-amidomethyloxazolidin-2-ones
US5182403A (en) * 1988-09-15 1993-01-26 The Upjohn Company Substituted 3(5'indazolyl) oxazolidin-2-ones
US5164510A (en) * 1988-09-15 1992-11-17 The Upjohn Company 5'Indolinyl-5β-amidomethyloxazolidin-2-ones
US5231188A (en) * 1989-11-17 1993-07-27 The Upjohn Company Tricyclic [6.5.51]-fused oxazolidinone antibacterial agents
CA2119556C (en) * 1991-11-01 2004-07-06 Michael Robert Barbachyn Substituted aryl- and heteroaryl-phenyloxazolidinones
SK283420B6 (sk) * 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
HUT74099A (en) * 1992-12-08 1996-11-28 Upjohn Co Tropone-substituted phenyloxazolidinone antibacterial agents and pharmaceutical compositions containing the same
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
EP0730591B1 (en) * 1993-11-22 1999-07-14 PHARMACIA & UPJOHN COMPANY Esters of substituted-hydroxyacetyl piperazine phenyl oxazolidinones
DE4425613A1 (de) * 1994-07-20 1996-01-25 Bayer Ag 5-gliedrige Heteroaryl-oxazolidinone
DE4425612A1 (de) * 1994-07-20 1996-04-04 Bayer Ag 6-gliedrige stickstoffhaltige Heteroaryl-oxazolidinone
DE4425609A1 (de) * 1994-07-20 1996-01-25 Bayer Ag Benzofuranyl- und Benzothienyloxazolidinone
DE19514313A1 (de) * 1994-08-03 1996-02-08 Bayer Ag Benzoxazolyl- und Benzothiazolyloxazolidinone
PT792273E (pt) * 1994-11-15 2003-06-30 Upjohn Co Produtos antibacterianos de oxazolidinona substituida com oxazina e tiazina biciclicas
HRP960159A2 (en) * 1995-04-21 1997-08-31 Bayer Ag Benzocyclopentane oxazolidinones containing heteroatoms
FI980452A7 (fi) * 1995-09-01 1998-02-27 Upjohn Co Fenyylioksatsolidinoneja, jotka ovat liittyneet C-C-sidoksella 4-8-jäs enisiin heterosyklisiin renkaisiin
DE19601264A1 (de) * 1996-01-16 1997-07-17 Bayer Ag Pyrido-annellierte Thienyl- und Furanyl-Oxazolidinone
DE19604223A1 (de) * 1996-02-06 1997-08-07 Bayer Ag Neue substituierte Oxazolidinone
US6239152B1 (en) * 1998-01-23 2001-05-29 Pharmacia & Upjohn Company Oxazolidinone combinatorial libraries, compositions and methods of preparation
MY122454A (en) * 1998-06-05 2006-04-29 Upjohn Co Use of oxazolidinones for the preparation of a medicament for transdermal delivery
ATE301474T1 (de) * 2000-06-30 2005-08-15 Pharmacia & Upjohn Co Llc Zusammensetzungen zur behandlung baktrieller infektionen, welche ein oxazolidinonderivat, sulbactam und ampicillin enthalten

Also Published As

Publication number Publication date
MXPA04009356A (es) 2005-01-25
IL164195A0 (en) 2005-12-18
US20030216330A1 (en) 2003-11-20
RU2354372C2 (ru) 2009-05-10
WO2003084534A1 (en) 2003-10-16
CA2476545A1 (en) 2003-10-16
EP1490059A1 (en) 2004-12-29
KR20040095328A (ko) 2004-11-12
CN1642543A (zh) 2005-07-20
AU2003223334A1 (en) 2003-10-20
PL372661A1 (en) 2005-07-25
ZA200407734B (en) 2005-06-24
JP2005527575A (ja) 2005-09-15
RU2004131830A (ru) 2005-04-10
NO20044672L (no) 2004-12-23
NZ535648A (en) 2007-05-31

Similar Documents

Publication Publication Date Title
BR0308806A (pt) Uso de oxazolidinonas para tratar infecções do tipo pé diabético
BRPI0415953A (pt) formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação
NO20061517L (no) Langvarig frigivelsesdoseingsform av Ziprasidon
WO2004032909A3 (en) Stabilized pharmaceutical composition containing basic excipients
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
CO5700796A2 (es) Composiciones que contienen piperacilina y tazobactam utiles para inyecciones
BRPI0809011A8 (pt) composto, composição farmacêutica, método de tratamento, controle ou prevenção de uma doença ou distúrbio, e, forma de dosagem unitária única
EA201000643A1 (ru) Замещенное производное этилендиамина для лечения микобактериальных заболеваний и фармацевтическая композиция на его основе
EA201170527A1 (ru) Фармацевтические композиции, включающие соединения бороновой кислоты
EA200200812A1 (ru) Фармацевтическая композиция, содержащая низкую дозу энтекавира, и ее применение
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
CR10166A (es) Uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento del trastorno bipolar y mania
ES2133324T3 (es) Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y metodos de uso.
AR062659A1 (es) Composicion de liberacion sostenida de levodopa y metodo para su uso
BR0110382A (pt) Utilização de composições antibióticas azalida para o tratamento ou prevenção de uma infecção causada por bactérias ou protozoários em mamìferos
EA200400548A1 (ru) Лечение тяжёлой пневмонии путём введения ингибитора пути тканевого фактора (tfpi)
BRPI0418742A (pt) métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
PL360492A1 (en) Use of pamoic acid or one of its derivatives, or one of its analogues, for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates
BRPI0507657A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
BRPI0517650A (pt) uso de ranolazina em combinação com pelo menos um agente de remodelamento para reversão de remodelamento ventricular esquerdo no tratamento de insuficiência cardìaca
BRPI0508079A (pt) composto ou uma forma cristalina ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, métodos de tratar ou prevenir uma infecção viral com hepatite c em um mamìfero e de inibir replicação de um vìrus da hepatite c
ATE376422T1 (de) Diclazurilhaltige antiprotozoenmittel
BR0011880A (pt) Método para o tratamento de condições co-mórbidas associadas com obesidade, composto, produto, uso de um composto, e, composição farmacêutica
EA200100010A1 (ru) Местное применение оксазолидинонов для трансдермальной доставки
AR029557A1 (es) Composicion para el uso en el tratamiento o la prevencion de la mastitis, y uso de oxazolidinona para la fabricacion de un medicamento para el tratamiento o la prevencion de la mastitis

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A, 8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 7A, 8A E 9A ANUIDADES.